Analyst Price Target is $30.50
▲ +893.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $30.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 893.49% upside from the last price of $3.07.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Tempest Therapeutics. This rating has held steady since July 2021, when it changed from a Hold consensus rating.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.